Results 61 to 70 of about 41,581 (185)

Novel reference gene microseminoprotein‐beta based prostate cancer antigen 3 urine test: Enhanced diagnostic performance for prostate cancer and feasibility of non‐digital rectal examination urine sampling

UroPrecision, EarlyView.
Abstract Background The diagnosis of prostate cancer (PCa) is limited by low specificity and invasiveness. This study aims to establish a highly accurate, noninvasive reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR)‐based urinary prostate cancer antigen 3 (PCA3) assay system and explore the feasibility of using first‐morning urine
Jianglei Xu, Lu Yang, Cong Shi, Yiwei Jiang, Jing Chen, Xiaoxiao Sun, Xuejuan Gao, Xian Wang, Jianzhong Jiang, Xiuzhi Duan, Xuchu Wang, Yiyi Xie, Zhixian Yu, Zhihua Tao, Xiaobing Dou, Chunyu Jin   +15 more
wiley   +1 more source

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES

Рациональная фармакотерапия в кардиологии, 2016
Large epidemiological trails shown that hypercholesterolemia is one of the main risk factor of ischemic heart disease (IHD). Correction of the hypercholesterolemia with GmGKoA reductase inhibitors (statins) essentially reduces IHD morbidity and mortality.
A. N. Meshkov
doaj   +1 more source

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, EarlyView.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Fenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats

Toxicology Reports
Atorvastatin and fenofibrate are well-known lipid-lowering drugs. Atorvastatin acts by reducing the production of cholesterol through the inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A reductase) enzyme, whereas fenofibrate ...
Sanjib Ghosh, Sweata Sarkar, Maharaj Biswas   +2 more
doaj   +1 more source

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, EarlyView.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source

Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-α in macrophages

Journal of Biomedical Science, 2009
Atorvastatin has been shown to reduce resistin expression in macrophages after pro-inflammatory stimulation. However, the mechanism of reducing resistin expression by atorvastatin is not known. Therefore, we sought to investigate the molecular mechanisms
Chua Su-Kiat, Shyu Kou-Gi, Wang Bao-Wai, Kuan Peiliang   +3 more
doaj   +1 more source

Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective

Immunology, EarlyView.
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac, Carolina do Prado Servian, Fernanda de Oliveira Feitosa de Castro, João Lucas Lima Calandrini de Azevedo, Ronaldo Moraes Preto, Miriam Leandro Dorta, Daniela Espíndola Antunes, Simone Gonçalves Fonseca   +7 more
wiley   +1 more source

Clinical Vignette: Piperacillin/tazobactam‐associated myoclonic status epilepticus in a patient with end‐stage renal failure on hemodialysis

Epileptic Disorders, EarlyView.
O. M. Malanga, G. Giovannelli, G. Pastorelli, S. Fittante, A. Poggesi, E. Rosati   +5 more
wiley   +1 more source

Nanoparticles in Periodontology and Implant Dentistry: From Mechanisms to Clinical Applications

Journal of Periodontal Research, EarlyView.
Nanotechnology holds significant promise in improving dental care, yet there is a need for more reliable clinical studies to validate its effectiveness and safety. ABSTRACT Recent advances in nanotechnology are reshaping the landscape of periodontology and implant dentistry, particularly through the application of nanoparticles (NPs).
Chun Xu, Yuan Chen, Mario Romandini, Håvard Jostein Haugen, Sašo Ivanovski   +4 more
wiley   +1 more source